Treatment of autoimmune disease: Time for a paradigm shift?

Archivum Immunologiae et Therapiae Experimentalis

Volumn 55, Issue 1, 2007, Pages 13-18

  Mor, Felix ^a,b,c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoimmune disease; Immune regulation; Immune suppression; Regulatory T cells

Indexed keywords

COLLAGEN TYPE 2; INSULIN; MYELIN BASIC PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; COLITIS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; MYOCARDITIS; NEPHRITIS; NEURITIS; NONHUMAN; ORCHITIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; THYROIDITIS; UVEITIS;

ALLERGY AND IMMUNOLOGY; ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; FORECASTING; HUMANS; INTERNAL MEDICINE;

EID: 33847123994     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-007-0002-1     Document Type: Review

References (74)

1. Achiron A., Lavie G., Kishner I., Stern Y., Sarova-Pinhas I., Ben-Aharon T., Barak Y., Raz H, Lavie M., Barliya T., Faibel M., Cohen I. R. and Mandel M. (2004): T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin. Immunol., 113, 155-160.
2. Bar-Or A., Oliveira E. M., Anderson D. E. and Hafler D. A. (1999): Molecular pathogenesis of multiple sclerosis. J. Neuroimmunol., 100, 252-259.
3. Bartt R. E. (2006): Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr. Opin. Neurol., 19, 341-349.
4. Beissert S., Schwarz A. and Schwarz T. (2006): Regulatory T cells. J. Invest. Dermatol., 126, 15-24.
5. Bell R. B. and Steinman L. (1991): Trimolecular interactions in experimental autoimmune demyelinating disease and prospects for immunotherapy. Semin. Immunol., 3, 237-345.
6. Ben-Nun A., Wekerle H. and Cohen I. R. (1981): Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature, 292, 60-61.
7. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J. A., McFarland H. F. and Martin R. (2000): Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med., 6, 1167-1175.
8. Blanas E., Carbone F. R., Allison J., Miller J. F. and Heath W. R. (1996): Induction of autoimmune diabetes by oral administration of autoantigen. Science, 274, 1707-1709.
9. Bluestone J. A. and Tang Q.(2004): Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc. Natl. Acad. Sci. USA, 101 (suppl. 2), 14622-14626.
10. Bongartz T., Sutton A. J., Sweeting M. J., Buchan I., Matteson E. L. and Montori V. (2006): Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 295, 2275-2285.
11. Bourdette D. N., Whitham R. H., Chou Y. K., Morrison W. J., Atherton J., Kenny C., Liefeld D., Hashim G. A., Offner H. and Vandenbark A. A. (1994): Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. J. Immunol., 152, 2510-2519.
12. Bresson D., Togher L., Rodrigo E., Chen Y., Bluestone J. A., Herold K. C. and von Herrath M. (2006): Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest., 116, 1371-1381.
13. Chatenoud L. and Bach J. F. (2005): Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance. Expert Opin. Biol. Ther., 5 (suppl. 1), S73-81.
14. Chen Y., Kuchroo V. K., Inobe J., Hafler D. A. and Weiner H. L. (1994): Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science, 265, 1237-1240.
15. Cohen I. R., Quintana F. J. and Mimran A. (2004): Tregs in T cell vaccination: exploring the regulation of regulation. J. Clin. Invest., 114, 1227-1232.
16. Cohen I. R. and Weiner H. L. (1988): T-cell vaccination. Immunol. Today, 9, 332-335.
17. Cong Y., Konrad A., Iqbal N., Hatton R. D., Weaver C. T. and Elson C. O. (2005): Generation of antigen-specific, Foxp3-expressing CD4+ regulatory T cells by inhibition of APC proteosome function. J. Immunol., 174, 2787-2795.
18. Deloire M. S., Touil T., Brochet B., Dousset V., Caille J. M. and Petry K. G. (2004): Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment. Mult. Scler., 10, 540-548.
19. Desquenne-Clark L., Esch T. R., Otvos L. Jr., Heber-Katz E. (1991): T-cell receptor peptide immunization leads to enhanced and chronic experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. USA, 88, 7219-7223.
20. Dittel B. N., Visintin I., Merchant R. M. and Janeway C. A. Jr. (1999): Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J. Immunol., 163, 32-39.
21. El Behi M., Dubucquoi S., Lefranc D., Zephir H., De Seze J., Vermersch P. and Prin L. (2005): New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Lett., 96, 11-26.
22. Figueiredo A. C., Cohen I. R. and Mor F.(1999): Diversity of the B cell repertoire to myelin basic protein in rat strains susceptible and resistant to EAE. J. Autoimmun., 12, 13-25.
23. Filippi C., Bresson D. and Von Herrath M. (2005): Antigen-specific induction of regulatory T cells for type 1 diabetes therapy. Int. Rev. Immunol., 24, 341-360.
24. Fisson S., Djelti F., Trenado A., Billiard F., Liblau R., Klatzmann D., Cohen J. L. and Salomon B. L. (2006): Therapeutic potential of self-antigen-specific CD4+ CD25+ regulatory T cells selected in vitro from a polyclonal repertoire. Eur. J. Immunol., 36, 817-827.
25. Ford M. L. and Evavold B. D. (2005): Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis. Eur. J. Immunol., 35, 76-85.
26. Gonsette R. E. (1996): Mitoxantrone immunotherapy in multiple sclerosis. Mult. Scler., 1, 329-332.
27. Hafler D. A., Cohen I., Benjamin D. S. and Weiner H. L. (1992): T cell vaccination in multiple sclerosis: a preliminary report. Clin. Immunol. Immunopathol., 62, 307-313.
28. Hellings N., Raus J. and Stinissen P. (2004): T-cell vaccination in multiple sclerosis: update on clinical application and mode of action. Autoimmun. Rev., 3, 267-275.
29. Hickey W. F., Hsu B. L. and Kimura H. (1991): T-lymphocyte entry into the central nervous system. J. Neurosci. Res., 28, 254-260.
30. Jee Y., Yoon W. K., Okura Y., Tanuma N. and Matsumoto Y. (2002): Upregulation of monocyte chemotactic protein-1 and CC chemokine receptor 2 in the central nervous system is closely associated with relapse of autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol., 128, 49-57.
31. Khoury S. J., Hancock W. W. and Weiner H. L. (1992): Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med., 176, 1355-1364.
32. Khoury S. J., Sayegh M. H., Hancock W. W., Gallon L., Carpenter C. B. and Weiner H. L. (1993): Acquired tolerance to experimental autoimmune encephalomyelitis by intrathymic injection of myelin basic protein or its major encephalitogenic peptide. J. Exp. Med., 178, 559-566.
33. Kumar V. (2004): Homeostatic control of immunity by TCR peptide-specific Tregs. J. Clin. Invest., 114, 1222-1226.
34. Kumar V., Kono D. H., Urban J. L. and Hood L. (1989): The T-cell receptor repertoire and autoimmune diseases. Annu. Rev. Immunol., 7, 657-682.
35. Lehmann P. V., Sercarz E. E., Forsthuber T., Dayan C. M. and Gammon G. (1993): Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol. Today, 14, 203-208.
36. Lider O., Reshef T., Beraud E., Ben-Nun A. and Cohen I. R. (1988): Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science, 239, 181-183.
37. Liu H. Y., Buenafe A. C., Matejuk A., Ito A., Zamora A., Dwyer J., Vandenbark A. A. and Offner H. (2002): Estrogen inhibition of EAE involves effects on dendritic cell function. J. Neurosci. Res., 70, 238-248.
38. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S. J., Oksenberg J. R., Raine C. S., Heller R. and Steinman L. (2002): Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med., 8, 500-508.
39. Lohse A. W., Mor F., Karin N. and Cohen I. R. (1989): Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells. Science, 244, 820-822.
40. Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Davis D., Macfarlane J. D., Antoni C., Leeb B., Elliott M. J., Woody J. N., Schaible T. F. and Feldmann M. (1998): Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum., 41, 1552-1563.
41. Maini R. N., Brennan F. M., Williams R., Chu C. Q., Cope A. P., Gibbons D., Elliott M. and Feldmann M. (1993): TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. Clin. Exp. Rheumatol., 11 (suppl. 8), S173-175.
42. Maron R., Blogg N. S., Polanski M., Hancock W. and Weiner H. L. (1996): Oral tolerance to insulin and the insulin B-chain: cell lines and cytokine patterns. Ann. NY Acad. Sci., 778, 346-357.
43. Masteller E. L., Warner M. R., Tang Q., Tarbell K. V., McDevitt H. and Bluestone J. A. (2005): Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J. Immunol., 175, 3053-3059.
44. Matsui M., Weaver J., Proudfoot A. E., Wujek J. R., Wei T., Richer E., Trapp B. D., Rao A. and Ransohoff R. M. (2002): Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. J. Neuroimmunol., 128, 16-22.
45. McFarland H. I., Lobito A. A., Johnson M. M., Nyswaner J. T., Frank J. A., Palardy G. R., Tresser N., Genain C. P., Mueller J. P., Matis L. A. and Lenardo M. J. (1999): Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis. J. Immunol., 162, 2384-2390.
46. Medh R. D. (2002): Microarray-based expression profiling of normal and malignant immune cells. Endocr. Rev., 23, 393-400.
47. Miura K., Bowman E. D., Simon R., Peng A. C., Robles A. I., Jones R. T., Katagiri T., He P., Mizukami H., Charboneau L., Kikuchi T., Liotta L. A., Nakamura Y. and Harris C. C. (2002): Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res., 62, 3244-3250.
48. Mor F., Boccaccio G. L. and Unger T. (1998): Expression of autoimmune disease-related antigens by cells of the immune system. J. Neurosci. Res., 54, 254-262.
49. Mor F., Lohse A. W., Karin N. and Cohen I. R. (1990): Clinical modeling of T cell vaccination against autoimmune diseases in rats. Selection of antigen-specific T cells using a mitogen. J. Clin. Invest., 85, 1594-1598.
50. Mor F., Reizis B., Cohen I. R. and Steinman L. (1996): IL-2 and TNF receptors as targets of regulatory T-T interactions: isolation and characterization of cytokine receptor-reactive T cell lines in the Lewis rat. J. Immunol., 157, 4855-4861.
51. Nishikawa H., Kato T., Tawara I., Saito K., Ikeda H., Kuribayashi K., Allen P. M., Schreiber R. D., Sakaguchi S., Old L. J. and Shiku H. (2005): Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J. Exp. Med., 201, 681-686.
52. Paniagua R. T., Sharpe O., Ho P. P., Chan S. M., Chang A., Higgins J. P., Tomooka B. H., Thomas F. M., Song J. J., Goodman S. B., Lee D. M., Genovese M. C., Utz P. J., Steinman L. and Robinson W. H. (2006): Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest., 116, 2633-2642.
53. Panitch H. S., Hirsch R. L., Haley A. S. and Johnson K. P. (1987): Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet, 1, 893-895.
54. Perrin P. J., Scott D., June C. H. and Racke M. K. (1995): B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis. Immunol. Res., 14, 189-199.
55. Rajan A. J., Gao Y. L., Raine C. S. and Brosnan C. F. (1996): A pathogenic role for gamma delta T cells in relapsing-remitting experimental allergic encephalomyelitis in the SJL mouse. J. Immunol., 157, 941-949.
56. Ransohoff R. M. (2005): Natalizumab and PML. Nat. Neurosci., 8, 1275.
57. Robinson W. H., Fontoura P., Lee B. J., de Vegvar H. E., Tom J., Pedotti R., DiGennaro C. D., Mitchell D. J., Fong D., Ho P. P., Ruiz P. J., Maverakis E., Stevens D. B., Bernard C. C., Martin R., Kuchroo V. K., van Noort J. M., Genain C. P., Amor S., Olsson T., Utz P. J., Garren H. and Steinman L. (2003): Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat. Biotechnol., 21, 1033-1039.
58. Roffe E., Souza A. L., Caetano B. C., Machado P. P., Barcelos L. S., Russo R. C., Santiago H. C., Souza D. G., Pinho V., Tanowitz H. B., Camargos E. R., Bruna-Romero O. and Teixeira M. M. (2006): A DNA vaccine encoding CCL4/MIP-1beta enhances myocarditis in experimental Trypanosoma cruzi infection in rats. Microbes Infect., 8, 2745-2755.
59. Schmied M., Breitschopf H., Gold R., Zischler H., Rothe G., Wekerle H. and Lassmann H. (1993): Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am. J. Pathol., 143, 446-452.
60. Sela M. and Teitelbaum D. (2001): Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin. Pharmacother., 2, 1149-1165.
61. Shoda L. K., Young D. L., Ramanujan S., Whiting C. C., Atkinson M. A., Bluestone J. A., Eisenbarth G. S., Mathis D., Rossini A. A., Campbell S. E., Kahn R. and Kreuwel H. T. (2005): A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity, 23, 115-126.
62. Steinman L. (2005): Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov., 4, 510-518.
63. Stosiek C., Garaschuk O., Holthoff K. and Konnerth A. (2003): In vivo two-photon calcium imaging of neuronal networks. Proc. Natl. Acad. Sci. USA, 100, 7319-7324.
64. Suntharalingam G., Perry M. R., Ward S., Brett S. J., Castello-Cortes A., Brunner M. D. and Panoskaltsis N. (2006): Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med., 355, 1018-1028.
65. Thorbecke G. J., Schwarcz R., Leu J., Huang C. and Simmons W. J. (1999): Modulation by cytokines of induction of oral tolerance to type II collagen. Arthritis Rheum., 42, 110-118.
66. Vandenbark A. A., Hashim G. and Offner H. (1989): Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature, 341, 541-544.
67. Veldman C., Nagel A. and Hertl M. (2006): Type I regulatory T cells in autoimmunity and inflammatory diseases. Int. Arch. Allergy Immunol., 140, 174-183.
68. Warren K. G. and Catz I. (1989): Cerebrospinal fluid autoantibodies to myelin basic protein in multiple sclerosis patients. Detection during first exacerbations and kinetics of acute relapses and subsequent convalescent phases. J. Neurol. Sci., 91, 143-151.
69. Weiner H. L. (2001): Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol. Rev., 182, 207-214.
70. Weiner H. L., Mackin G. A., Matsui M., Orav E. J., Khoury S. J., Dawson D. M. and Hafler D. A. (1993): Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science, 259, 1321-1324.
71. Wekerle T., Kurtz J., Bigenzahn S., Takeuchi Y. and Sykes M. (2002): Mechanisms of transplant tolerance induction using costimulatory blockade. Curr. Opin. Immunol., 14, 592-600.
72. Yarom Y., Naparstek Y., Lev-Ram V., Holoshitz J., Ben-Nun A. and Cohen I. R. (1983): Immunospecific inhibition of nerve conduction by T lymphocytes reactive to basic protein of myelin. Nature, 303, 246-247.
73. Zhang I. and Raus J. (1996): T cell vaccination in multiple sclerosis. Mult. Scler., 1, 353-356.
74. Zhang J., Medaer R., Stinissen P., Hafler D. and Raus J. (1993): MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science, 261, 1451-1454.